Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Benmelstobart and HAIC for Unresectable Hepatocellular Carcinoma
NCT07806292Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, benmelstobart in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen Memorial Hospital. Started Apr 2025; status: recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07806292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806292.